News
TNXP
0.5460
-5.78%
-0.0335
Tonix Pharma gains on FDA fast track tag for pain therapy
Tonix Pharmaceuticals gains on FDA fast track tag for pain therapy. The company's non-opioid pain therapy Tonmya. The FDA has issued the fast-track designation for the drug's use in the management of fibromyalgia. Tonix plans to submit a marketing application in H2 2024.
Seeking Alpha · 1d ago
Tonix Pharma Accelerates Fibromyalgia Treatment with FDA Fast Track
TipRanks · 1d ago
TONIX PHARMACEUTICALS GRANTED FAST TRACK DESIGNATION BY FDA FOR TONMYA™ FOR FIBROMYALGIA
Reuters · 1d ago
TONIX PHARMACEUTICALS HOLDING: EXPECTS FINANCIAL STATEMENTS FOR QUARTER ENDED JUNE 30, 2024 WILL REFLECT A NON-CASH IMPAIRMENT OF ABOUT $50 MLN
Reuters · 2d ago
Tonix Pharmaceuticals Price Target Raised to $11.00/Share From $6.00 by Alliance Global Partners
Dow Jones · 4d ago
Tonix Pharmaceuticals Is Maintained at Buy by Alliance Global Partners
Dow Jones · 4d ago
Alliance Global Partners Maintains Buy on Tonix Pharmaceuticals, Raises Price Target to $11
Benzinga · 4d ago
TONIX PHARMACEUTICALS HOLDING CORP <TNXP.O>: ALLIANCE GLOBAL PARTNERS RAISES TARGET PRICE TO $11 FROM $6
Reuters · 4d ago
Weekly Report: what happened at TNXP last week (0715-0719)?
Weekly Report · 4d ago
TONIX PHARMACEUTICALS HOLDING CORP -SET TO FILE AN NDA FOR TONMYA FOR THE MANAGEMENT OF FIBROMYALGIA, IS PLANNING EXPECTED LAUNCH IN 2H 2025
Reuters · 07/17 12:04
Tonix Pharmaceuticals, Set To File An NDA For Tonmya For The Management Of Fibromyalgia, Assuming Approval By The FDA In 2H 2025
Benzinga · 07/17 12:04
Tonix Pharma Updates Investors on CD45 Candidate Developments
TipRanks · 07/16 13:28
Weekly Report: what happened at TNXP last week (0708-0712)?
Weekly Report · 07/15 11:21
TONIX PHARMACEUTICALS ANNOUNCES CLOSING OF $4.0 MILLION PUBLIC OFFERING
Reuters · 07/10 20:30
Press Release: Tonix Pharmaceuticals Announces Closing of $4.0 Million Public Offering
Dow Jones · 07/10 20:30
Why Helen of Troy Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Helen of Troy Limited shares dipped 30.3% to $62.06 on Tuesday. The company reported soft first-quarter earnings and lowered its FY25 guidance. Soligenix, Inc. Shares jumped 195% after the company announced interim results for extended HyBryte treatment in early-stage patients.
Benzinga · 07/09 16:59
TONIX PHARMACEUTICALS HOLDING CORP - TO SELL 7.1 MLN SHARES AT $0.57 PER SHARE
Reuters · 07/09 13:15
Why Mainz Biomed Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
Mainz Biomed shares jumped 16% in today's pre-market trading. Pineapple Energy Inc. Shares rose 85% to $2.22 in pre- market trading. The company announced submission for the FDA Breakthrough Device Designation for its next generation CRC screening test.
Benzinga · 07/09 09:33
Tonix Pharmaceuticals Announces Pricing of Approximately $4.0 Million Public Offering
Tonix Pharmaceuticals Holding Corp. Has entered into a placement agency agreement for the purchase and sale of 7,096,740 shares of its common stock. The closing of the public offering is expected to take place on or about July 10, 2024. Tonix is a fully-integrated biopharmaceutical company.
Barchart · 07/09 08:15
Tonix Pharma To Offer And Sell Shares Of Common Stock
NASDAQ · 07/09 01:06
More
Webull provides a variety of real-time TNXP stock news. You can receive the latest news about Tonix Pharmaceut through multiple platforms. This information may help you make smarter investment decisions.
About TNXP
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include Tonmya (TNX-102 SL), TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801 and TNX-1800. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.